Comments
Loading...

Alnylam Pharmaceuticals Calificaciones de analistas

ALNYNASDAQ
Logotipo presentado por Benzinga Data
$460.46
3.510.77%
al cierre: -
$457.42
-3.04-0.66%
After hour: Oct 10, 4:16 PM EDT
Calificación de consenso1
Buy
Precio objetivo más alto1
$583.00
Precio objetivo más bajo1
$220.00
Precio objetivo consensuado1
$448.97

Calificaciones de analistas, precios objetivo, pronóstico

Alnylam Pharmaceuticals Inc ha un obiettivo di prezzo di consenso pari a $448.97, stabilito in base alle ultime valutazioni degli analisti di 29. Le ultime 3 valutazioni degli analisti sono state rilasciate da HC Wainwright & Co., Morgan Stanley y Stifel il octubre 10, 2025, octubre 6, 2025 y octubre 6, 2025. Con un obiettivo di prezzo medio di $513.33 tra le HC Wainwright & Co., Morgan Stanley y Stifel, c'è un implicito 12.22% upside per Alnylam Pharmaceuticals Inc da queste valutazioni degli analisti.

Tendencia de los analistas
7
jul
9
2
ago
7
sept
2
1
oct
Compra
Mantener
Venta
Venta fuerte
Calificación de analistas
12345
3.8
Compra
Compra fuerte
Compra
Mantener
Venta
Venta fuerte

Firmas de analistas que realizan recomendaciones1

HC Wainwright & Co.
Morgan Stanley
Stifel
RBC Capital
B of A Securities

1calculado a partir de las calificaciones de los analistas

Calificaciones de analistas para Alnylam Pharmaceuticals

Buy Now
Get Alert
10/10/2025
24.61%
HC Wainwright & Co.
$570 → $570
Reiterates
Buy → Buy
10/06/2025
3.84%
Morgan Stanley
$405 → $475
Maintains
Equal-Weight
10/06/2025
8.22%
Stifel
$441 → $495
Maintains
Buy
09/19/2025
9.31%
RBC Capital
$435 → $500
Maintains
Outperform
09/17/2025
13.68%
B of A Securities
$453 → $520
Maintains
Buy
09/16/2025
23.74%
Goldman Sachs
$504 → $566
Maintains
Buy
09/11/2025
12.6%
Evercore ISI Group
$280 → $515.05
Maintains
Outperform
09/08/2025
2.75%
BMO Capital
$450 → $470
Maintains
Outperform
09/02/2025
24.61%
HC Wainwright & Co.
$570 → $570
Reiterates
Buy → Buy
09/02/2025
27.45%
Citigroup
$527 → $583
Maintains
Buy
08/07/2025
24.61%
HC Wainwright & Co.
$500 → $570
Maintains
Buy
08/06/2025
3.84%
JP Morgan
$348 → $475
Maintains
Overweight
08/04/2025
7.12%
Oppenheimer
→ $490
Upgrade
Perform → Outperform
08/04/2025
Wolfe Research
Upgrade
Underperform → Peer Perform
08/01/2025
-1.62%
Scotiabank
$342 → $450
Maintains
Sector Outperform
08/01/2025
20.24%
UBS
$403 → $550
Maintains
Buy
08/01/2025
-9.27%
Canaccord Genuity
$390 → $415
Maintains
Buy
08/01/2025
-13.65%
Wells Fargo
$333 → $395
Maintains
Equal-Weight
08/01/2025
-7.31%
Raymond James
$370 → $424
Reiterates
Outperform → Outperform
08/01/2025
0.56%
Barclays
$329 → $460
Maintains
Overweight
08/01/2025
-1.84%
Piper Sandler
$304 → $449
Maintains
Overweight
08/01/2025
-12.55%
Chardan Capital
$325 → $400
Maintains
Buy
08/01/2025
-11.46%
Morgan Stanley
$312 → $405
Maintains
Equal-Weight
07/31/2025
4.5%
Needham
$377 → $478
Maintains
Buy
07/29/2025
-19.11%
Raymond James
$308 → $370
Assumes
Outperform → Outperform
07/21/2025
-15.83%
Truist Securities
→ $385
Initiates
→ Buy
07/16/2025
-23.92%
JP Morgan
$338 → $348
Maintains
Overweight
07/11/2025
-11.68%
Citigroup
$364 → $404
Maintains
Buy
07/11/2025
-21.52%
B of A Securities
$336 → $359
Maintains
Buy
07/07/2025
-16.05%
Jefferies
$328 → $384
Maintains
Buy
06/30/2025
-27.2%
Wells Fargo
$287 → $333
Maintains
Equal-Weight
06/26/2025
-17.58%
Needham
$320 → $377
Maintains
Buy
06/24/2025
-21.3%
BMO Capital
$300 → $360
Maintains
Outperform
06/12/2025
-26.11%
JP Morgan
$330 → $338
Maintains
Overweight
05/02/2025
-23.7%
UBS
$331 → $349
Maintains
Buy
05/02/2025
-28.95%
Chardan Capital
$300 → $325
Maintains
Buy
04/11/2025
-41.41%
Morgan Stanley
$284 → $268
Maintains
Equal-Weight
04/09/2025
-30.04%
Needham
$320 → $320
Reiterates
Buy → Buy
04/02/2025
9.31%
HC Wainwright & Co.
$500 → $500
Reiterates
Buy → Buy
03/31/2025
-25.23%
Scotiabank
$338 → $342
Maintains
Sector Outperform
03/31/2025
-22.83%
Redburn Atlantic
→ $353
Initiates
→ Buy
03/31/2025
-24.58%
Stifel
$300 → $345
Maintains
Buy
03/24/2025
-28.29%
JP Morgan
$280 → $328
Upgrade
Neutral → Overweight
03/21/2025
-23.26%
Citigroup
$338 → $351
Maintains
Buy
03/21/2025
-14.74%
Canaccord Genuity
$385 → $390
Maintains
Buy
03/21/2025
-27.86%
RBC Capital
$310 → $330
Maintains
Outperform
03/21/2025
-26.11%
Scotiabank
$300 → $338
Maintains
Sector Outperform
03/21/2025
-37.26%
Wells Fargo
$275 → $287
Maintains
Equal-Weight
03/21/2025
-28.95%
B of A Securities
$302 → $325
Maintains
Buy
03/21/2025
-34.41%
Chardan Capital
$300 → $300
Maintains
Buy
03/21/2025
-30.04%
Needham
$320 → $320
Reiterates
Buy → Buy
03/11/2025
-38.79%
JP Morgan
$272 → $280
Maintains
Neutral
02/26/2025
-32.23%
RBC Capital
$310 → $310
Reiterates
Outperform → Outperform
02/26/2025
-34.41%
Chardan Capital
$300 → $300
Maintains
Buy
02/26/2025
-30.04%
Needham
$320 → $320
Reiterates
Buy → Buy
02/25/2025
9.31%
HC Wainwright & Co.
$400 → $500
Reiterates
Buy → Buy
02/24/2025
9.31%
HC Wainwright & Co.
$400 → $500
Maintains
Buy
02/18/2025
-15.83%
Canaccord Genuity
$384 → $385
Maintains
Buy
02/14/2025
-34.41%
Scotiabank
$310 → $300
Maintains
Sector Outperform
02/14/2025
-37.91%
Morgan Stanley
$275 → $284
Maintains
Equal-Weight
02/14/2025
-30.04%
Needham
$320 → $320
Reiterates
Buy → Buy
02/11/2025
-34.41%
RBC Capital
$300 → $300
Reiterates
Outperform → Outperform
01/21/2025
-34.41%
RBC Capital
$300 → $300
Reiterates
Outperform → Outperform
01/13/2025
-12.55%
HC Wainwright & Co.
$400 → $400
Reiterates
Buy → Buy
01/13/2025
-30.04%
Needham
$320 → $320
Reiterates
Buy → Buy
01/07/2025
-32.23%
Bernstein
$314 → $310
Maintains
Outperform
11/18/2024
-35.29%
Piper Sandler
$296 → $296
Reiterates
Overweight → Overweight
11/18/2024
-12.55%
HC Wainwright & Co.
$400 → $400
Reiterates
Buy → Buy
11/12/2024
Wolfe Research
Downgrade
Peer Perform → Underperform
11/04/2024
-12.55%
HC Wainwright & Co.
$400 → $400
Reiterates
Buy → Buy
11/01/2024
-34.85%
Raymond James
$275 → $298
Maintains
Outperform
11/01/2024
-34.41%
RBC Capital
$300 → $300
Reiterates
Outperform → Outperform
11/01/2024
-32.23%
Scotiabank
$305 → $310
Maintains
Sector Outperform
11/01/2024
-28.07%
Barclays
$295 → $329
Maintains
Overweight
11/01/2024
-16.05%
Canaccord Genuity
$366 → $384
Maintains
Buy
11/01/2024
-34.41%
Chardan Capital
$300 → $300
Maintains
Buy
11/01/2024
-30.04%
Needham
$320 → $320
Reiterates
Buy → Buy
10/21/2024
-18.89%
TD Cowen
$282 → $371
Maintains
Buy
10/18/2024
-12.55%
HC Wainwright & Co.
$400 → $400
Reiterates
Buy → Buy
10/16/2024
-33.32%
Scotiabank
→ $305
Initiates
→ Sector Outperform
10/14/2024
-31.35%
B of A Securities
$307 → $314
Maintains
Buy
10/11/2024
-34.41%
Chardan Capital
$300 → $300
Maintains
Buy
10/11/2024
-51.9%
Cantor Fitzgerald
$220 → $220
Reiterates
Neutral → Neutral
10/10/2024
-34.41%
RBC Capital
$300 → $300
Reiterates
Outperform → Outperform
10/10/2024
-30.04%
Needham
$320 → $320
Reiterates
Buy → Buy
09/19/2024
-34.41%
RBC Capital
$300 → $300
Reiterates
Outperform → Outperform
09/09/2024
-51.9%
Cantor Fitzgerald
$220 → $220
Reiterates
Neutral → Neutral
09/04/2024
-34.41%
RBC Capital
$300 → $300
Reiterates
Outperform → Outperform
09/04/2024
-32.88%
B of A Securities
$295 → $307
Maintains
Buy
08/30/2024
-12.55%
HC Wainwright & Co.
$400 → $400
Reiterates
Buy → Buy
08/26/2024
-38.79%
JP Morgan
$248 → $280
Maintains
Neutral
08/20/2024
-12.55%
HC Wainwright & Co.
$400 → $400
Reiterates
Buy → Buy
08/16/2024
-19.11%
Goldman Sachs
$198 → $370
Upgrade
Neutral → Buy
08/02/2024
-34.41%
RBC Capital
$265 → $300
Maintains
Outperform
08/02/2024
-49.06%
Wells Fargo
$207 → $233
Maintains
Equal-Weight
08/02/2024
-39.88%
Raymond James
$242 → $275
Maintains
Outperform
08/02/2024
-56.71%
Goldman Sachs
$174 → $198
Maintains
Neutral
08/02/2024
-25.23%
Citigroup
$291 → $342
Maintains
Buy
08/02/2024
-35.51%
Barclays
$291 → $295
Maintains
Overweight
08/02/2024
-19.99%
Canaccord Genuity
$357 → $366
Maintains
Buy

PREGUNTAS FRECUENTES

Q

¿Cuál es el precio objetivo de las acciones de Alnylam Pharmaceuticals (ALNY)?

A

El último precio objetivo de Alnylam Pharmaceuticals (NASDAQ:ALNY) fue comunicado por HC Wainwright & Co. el octubre 10, 2025. La firma de analistas fijó un precio objetivo para $570.00 que espera ALNY a rise dentro de 12 meses (un posible 24.61% upside). 81 firmas de analistas han reportado calificaciones en el último año.

Q

¿Cuál es la calificación más reciente de los analistas sobre Alnylam Pharmaceuticals (ALNY)?

A

La última calificación de analistas para Alnylam Pharmaceuticals (NASDAQ:ALNY) fue proporcionada por HC Wainwright & Co., y Alnylam Pharmaceuticals reiterado su buy calificación.

Q

¿Cuándo se produjo la última revisión al alza de Alnylam Pharmaceuticals (ALNY)?

A

La última revisión al alza de Alnylam Pharmaceuticals Inc se produjo en agosto 4, 2025, cuando Oppenheimer elevó su precio objetivo a $490. Oppenheimer anteriormente tenía a perform para Alnylam Pharmaceuticals Inc.

Q

¿Cuándo fue la última revisión a la baja de Alnylam Pharmaceuticals (ALNY)?

A

La última revisión a la baja de Alnylam Pharmaceuticals Inc se produjo en noviembre 12, 2024, cuando Wolfe Research cambió su precio objetivo de N/A a N/A para Alnylam Pharmaceuticals Inc.

Q

¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Alnylam Pharmaceuticals (ALNY)?

A

Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Alnylam Pharmaceuticals, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Alnylam Pharmaceuticals se registró el octubre 10, 2025, por lo que la próxima calificación estará disponible en torno al octubre 10, 2026.

Q

¿Es correcta la calificación de los analistas sobre Alnylam Pharmaceuticals (ALNY)?

A

Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Alnylam Pharmaceuticals (ALNY) fue un reiterado con un precio objetivo de $570.00 a $570.00. El precio actual al que cotiza Alnylam Pharmaceuticals (ALNY) es de $457.42, que es out of del rango previsto por el analista.

Explora calificaciones de analistas y precios objetivo sobre todos los valores.

La gente también mira